US Stock MarketDetailed Quotes
MTNB Matinas BioPharma
- 0.1577
- -0.0216-12.05%
Close Jul 22 16:00 ET
- 0.1634
- +0.0057+3.61%
Post 18:01 ET
39.55MMarket Cap-1433P/E (TTM)
0.1818High0.1538Low2.76MVolume0.1765Open0.1793Pre Close451.85KTurnover1.13%Turnover RatioLossP/E (Static)250.82MShares0.890052wk High2.72P/B38.55MFloat Cap0.110352wk Low--Dividend TTM244.48MShs Float3.9500Historical High--Div YieldTTM15.62%Amplitude0.1103Historical Low0.1630Avg Price1Lot Size
Matinas BioPharma Stock Forum
Sign in to post a comment
$Matinas BioPharma(MTNB.US$ Reuters· 1 min ago
Matinas BioPharma Reports Successful Treatment of Patient With Limb-Threatening Mucor Infection in Its Oral Mat2203 Compassionate/Expanded Use Access Program
Matinas BioPharma Reports Successful Treatment of Patient With Limb-Threatening Mucor Infection in Its Oral Mat2203 Compassionate/Expanded Use Access Program
2
1
$Matinas BioPharma(MTNB.US$ New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
3 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of L...
3 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of L...
$Matinas BioPharma(MTNB.US$ Key Program Updates MAT2203 (Oral Amphotericin B) Program Phase 3 ORALTO Registration Trial ● Matinas reached alignment with the FDA on the design of a single Phase 3 registration trial of oral MAT2203 in patients with invasive aspergillosis who have limited treatment options. This is a serious and life-threatening invasive fungal infection that occurs primarily in severely immunocompromised patients, including those with hematological malignancies...
4
$Matinas BioPharma(MTNB.US$ Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
1 MINUTE AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel
Results build on data from prior in vivo study of oral LNC-docetaxel showing reductions in tumor size comparable to IV-doce...
1 MINUTE AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel
Results build on data from prior in vivo study of oral LNC-docetaxel showing reductions in tumor size comparable to IV-doce...
1
5
$Matinas BioPharma(MTNB.US$ My final scale is .4013!
$Matinas BioPharma(MTNB.US$ Matinas BioPharma Announces Complete Clinical Response In Three Patients With Serious Invasive Fusarium Infection Following Treatment With MAT2203
$Matinas BioPharma(MTNB.US$ Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
5 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE![]()
5 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
104681729 :
